Company intelligence / Profile preview
Probionase Therapies
Montreal, Quebec, Canadafacebook.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
A preliminary trial showed that twice-daily intranasal irrigation with Lactococcus lactis W136 was well tolerated by healthy volunteers and improved symptoms in patients with chronic rhinosinusitis refractory to standard treatments. A separate study suggested benefit in reducing moderate/severe COVID‑19 symptoms when initiated within four days of diagnosis compared to saline alone.
- Therapeutic areas
- ImmunologyPulmonologyInfectious Diseases
- Modalities
- Live biotherapeutic product therapyMicrobial therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Not specified
Beyond the preview
Go deeper on Probionase Therapies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Probionase Therapies.